Efficacy observation on imatinib adjuvant therapy with longer duration in patients with gastrointestinal stromal at intermediate or high risk of recurrence.
- Author:
Jian LI
1
;
Yun-zhi DANG
;
Jing GAO
;
Lin SHEN
Author Information
- Publication Type:Journal Article
- MeSH: Adult; Aged; Benzamides; administration & dosage; therapeutic use; Chemotherapy, Adjuvant; Disease-Free Survival; Female; Follow-Up Studies; Gastrointestinal Neoplasms; drug therapy; Gastrointestinal Stromal Tumors; drug therapy; Humans; Imatinib Mesylate; Male; Middle Aged; Neoplasm Recurrence, Local; Piperazines; administration & dosage; therapeutic use; Pyrimidines; administration & dosage; therapeutic use; Retrospective Studies; Treatment Outcome
- From: Chinese Journal of Gastrointestinal Surgery 2013;16(3):216-220
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVETo evaluate the recurrence-free survival (RFS) and safety of imatinib adjuvant therapy with longer treatment duration in patients undergoing complete resection of localized primary gastrointestinal stromal tumor (GIST).
METHODSClinical and follow-up data of 101 GIST patients between March 2004 and May 2009 with intermediate or high recurrence risk receiving imatinib adjuvant treatment and more than 3 years follow-up time in Peking University Cancer Hospital were retrospectively analyzed. Imatinib adjuvant treatment: 3 patients discontinued less than 1 year imatinib treatment because of adverse events; 24, 21 and 18 patients discontinued imatinib after 1 year, 2 years, and 3 years treatment; 8 patients received 3 years adjuvant treatment and were ongoing; 27 patients received more than 4 years imatinib adjuvant treatment.
RESULTSThe median follow-up time was 60 months (95%CI:57.9-62.1). Nineteen patients had GIST recurrence, of whom recurrence happened during imatinib adjuvant therapy in 5 patients and after imatinib treatment in 14 patients. The median period from imatinib stopping to recurrence was 12.0 months (95%CI:9.6-14.4). Patients with recurrent GIST achieved tumor control after imatinib resumption. RFS of patients (n=53) with ≥3 years imatinib treatment duration was higher than that of patients (n=48) with <3 years imatinib duration (93.9% vs. 68.0%, P<0.01). In addition, prolonged adjuvant imatinib duration did not significantly increase the adverse events related to treatment (P>0.05).
CONCLUSIONSProlonged adjuvant imatinib duration may further improve RFS rate further in patients with intermediate or high risk of recurrence after complete tumor resection without increased adverse events.